290 related articles for article (PubMed ID: 36101520)
1. MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC.
Tyler LC; Le AT; Chen N; Nijmeh H; Bao L; Wilson TR; Chen D; Simmons B; Turner KM; Perusse D; Kasibhatla S; Christiansen J; Dudek AZ; Doebele RC
Thorac Cancer; 2022 Nov; 13(21):3032-3041. PubMed ID: 36101520
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of Resistance to Tyrosine Kinase Inhibitors in ROS1 Fusion-Positive Nonsmall Cell Lung Cancer.
Zhao X; Zhang X; Chen H; Bao H; Wu X; Wang H; Bao H; Pang J; Wang S; Wang J
Clin Chem; 2024 Apr; 70(4):629-641. PubMed ID: 38416709
[TBL] [Abstract][Full Text] [Related]
3. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs MG; Shaw AT; de Braud F; Rolfo C; Ahn MJ; Wolf J; Seto T; Cho BC; Patel MR; Chiu CH; John T; Goto K; Karapetis CS; Arkenau HT; Kim SW; Ohe Y; Li YC; Chae YK; Chung CH; Otterson GA; Murakami H; Lin CC; Tan DSW; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Doebele RC;
Lancet Oncol; 2020 Feb; 21(2):261-270. PubMed ID: 31838015
[TBL] [Abstract][Full Text] [Related]
4. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.
Ku BM; Bae YH; Lee KY; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2020 Apr; 38(2):360-368. PubMed ID: 31124056
[TBL] [Abstract][Full Text] [Related]
5. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
6. MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by
Sato H; Schoenfeld AJ; Siau E; Lu YC; Tai H; Suzawa K; Kubota D; Lui AJW; Qeriqi B; Mattar M; Offin M; Sakaguchi M; Toyooka S; Drilon A; Rosen NX; Kris MG; Solit D; De Stanchina E; Davare MA; Riely GJ; Ladanyi M; Somwar R
Clin Cancer Res; 2020 Jun; 26(12):2932-2945. PubMed ID: 32122926
[TBL] [Abstract][Full Text] [Related]
7. Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.
Jorge SE; Schulman S; Freed JA; VanderLaan PA; Rangachari D; Kobayashi SS; Huberman MS; Costa DB
Lung Cancer; 2015 Dec; 90(3):369-74. PubMed ID: 26791794
[TBL] [Abstract][Full Text] [Related]
8. Resistance Mechanisms to Targeted Therapies in
McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
[No Abstract] [Full Text] [Related]
9. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
Sartore-Bianchi A; Pizzutilo EG; Marrapese G; Tosi F; Cerea G; Siena S
Expert Rev Anticancer Ther; 2020 May; 20(5):333-341. PubMed ID: 32223357
[No Abstract] [Full Text] [Related]
10. Intrinsic resistance to ROS1 inhibition in a patient with CD74-ROS1 mediated by AXL overexpression.
Peters TL; Chen N; Tyler LC; Le AT; Dimou A; Doebele RC
Thorac Cancer; 2023 Nov; 14(33):3259-3265. PubMed ID: 37727007
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles.
Terrones M; Deben C; Rodrigues-Fortes F; Schepers A; de Beeck KO; Van Camp G; Vandeweyer G
J Transl Med; 2024 Mar; 22(1):234. PubMed ID: 38433235
[TBL] [Abstract][Full Text] [Related]
12. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332
[TBL] [Abstract][Full Text] [Related]
13. Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.
Wang Y; Chen Z; Han X; Li J; Guo H; Shi J
Oncologist; 2021 Mar; 26(3):178-181. PubMed ID: 33000474
[TBL] [Abstract][Full Text] [Related]
14. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
Katayama R; Kobayashi Y; Friboulet L; Lockerman EL; Koike S; Shaw AT; Engelman JA; Fujita N
Clin Cancer Res; 2015 Jan; 21(1):166-74. PubMed ID: 25351743
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.
Park S; Ahn BC; Lim SW; Sun JM; Kim HR; Hong MH; Lee SH; Ahn JS; Park K; Choi Y; Cho BC; Ahn MJ
J Thorac Oncol; 2018 Sep; 13(9):1373-1382. PubMed ID: 29883837
[TBL] [Abstract][Full Text] [Related]
16. An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.
Dziadziuszko R; Le AT; Wrona A; Jassem J; Camidge DR; Varella-Garcia M; Aisner DL; Doebele RC
J Thorac Oncol; 2016 Aug; 11(8):1273-1281. PubMed ID: 27068398
[TBL] [Abstract][Full Text] [Related]
17. ROS1-rearranged Non-small Cell Lung Cancer.
Giustini NP; Bazhenova L
Thorac Surg Clin; 2020 May; 30(2):147-156. PubMed ID: 32327173
[TBL] [Abstract][Full Text] [Related]
18. CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib.
Gou W; Zhou X; Liu Z; Wang L; Shen J; Xu X; Li Z; Zhai X; Zuo D; Wu Y
Cancer Lett; 2018 May; 422():19-28. PubMed ID: 29477381
[TBL] [Abstract][Full Text] [Related]
19. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
[TBL] [Abstract][Full Text] [Related]
20. MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements.
Takumi Y; Arai S; Suzuki C; Fukuda K; Nishiyama A; Takeuchi S; Sato H; Matsumoto K; Sugio K; Yano S
Cancer Med; 2023 Mar; 12(5):5809-5820. PubMed ID: 36416133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
